Intravitreal Bevacizumab in Agioid Streaks
Keywords
Abstract
Description
To investigate the safety and efficacy of intravitreal bevacizumab in a patient with choroidal neovascularization associated with angioid streaks. One of the most serious ocular complication of angioid streaks is the occurrence of choroidal neovascularization (CNV) and because of the implication of the macula, this complication usually leads to central vision loss.
During the past, laser photocoagulation, first, and photodynamic therapy (PDT), more recently, have been used as treatment for this kind of CNV. The outcome of these therapies was often variable and sometimes disappointing for the stabilization of visual acuity and lesion size in CNV secondary to AS.
Five patients (six eyes) with CNV secondary to AS participated in this retrospective interventional case series. All patients were scheduled for three monthly IVB injections (1.25 mg). Two eyes had been previously treated with photodynamic therapy (PDT), and four received IVB as first choice treatment. IVB was repeated in case of recurrence after the three monthly IVB schedule. Ophthalmic evaluations included: best corrected visual acuity (BCVA) determination (ETDRS), optical coherence tomography (OCT), fluorescein and indocyanine green angiographies. Main outcome measures were BCVA improvement, reduction of leakage from CNV and diminution of central retinal thickness (CRT). Patients were followed-up for 30 months. Patients were 3 males and 2 females aged 44 to 67 years (mean 51.6 +/- 9.07 SD), who received a mean number of 4.33 IB treatments (+/-1.5; min: 3, max: 7). The mean retreatment interval was 3 months (+/-1.36; min: 2, max: 6).
Four eyes (66.6%) showed a BCVA improvement (mean 3.4 lines) from baseline and two eyes (33.3%) did not show any change in visual acuity from baseline to last follow-up. Mean BCVA rose significantly from 22.5+/-14.4 letters at baseline to 35.8+/-21.5 letters at 30 months (p=0.025). Angiographic examinations showed reduction or cessation of the CNV leakage in all patients. OCT findings demonstrated slight CRT diminution (mean 41.6 µm). No intraocular pressure changes were observed after the IVB injection, which did not cause any systemic complication. No injection related back pain or IVB-induced ocular complication was reported.
Dates
| Last Verified: | 01/31/2016 |
| First Submitted: | 11/29/2006 |
| Estimated Enrollment Submitted: | 11/29/2006 |
| First Posted: | 12/03/2006 |
| Last Update Submitted: | 02/04/2016 |
| Last Update Posted: | 02/07/2016 |
| Actual Study Start Date: | 10/31/2006 |
| Estimated Primary Completion Date: | 11/30/2008 |
| Estimated Study Completion Date: | 04/30/2009 |
Condition or disease
Intervention/treatment
Drug: Bevacizumab
Drug: Bevacizumab
Phase
Arm Groups
| Arm | Intervention/treatment |
|---|---|
| Experimental: Bevacizumab | Drug: Bevacizumab 1.25 mg in 0.05 cc of bevacizumab |
Eligibility Criteria
| Ages Eligible for Study | 44 Years To 44 Years |
| Sexes Eligible for Study | All |
| Accepts Healthy Volunteers | Yes |
| Criteria | Inclusion Criteria: - presence of an active CNV - visual loss - increased retinal thickness Exclusion Criteria: - no actively leaking CNV by FAG - normal retinal thickness - satisfactory visual acuity |
Outcome
Primary Outcome Measures
1. BCVA improvement [6 months]
Secondary Outcome Measures
1. reduction or cessation leakage [6 months]
